Peter J. Trainer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter J. Trainer has a total of 572 co-authors. Here are the top co-authors by number of shared publications:
G. M. Besser
Endocrinology, St Bartholomew’s Hospital, London, UK and
13 shared publications- Claire Emily Higham
Department of Endocrinology, The Christie NHS Foundation Trust, Manchester M20 4BX
11 shared publications - Márta Korbonits
Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London , London EC1M 6BQ
9 shared publications G M Besser
8 shared publicationsC. Parkinson
Department of Diabetes and Endocrinology (C.P.), The Ipswich Hospital, Ipswich IP4 5PD, United Kingdom
6 shared publications- David William Ray
NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
6 shared publications
Latest Publications
- Open Access
- 3 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 228-237
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine
Context Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. Objective To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs). Methods This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had insulin-like growth factor I (IGF-I) ≤1.0 times the upper limit of normal (×ULN) while receiving a stable dose of depot octreotide or lanreotide. Patients were switched from injected SRLs and randomized to receive paltusotine or placebo orally for 36 weeks. The primary endpoint was proportion of patients maintaining IGF-I ≤1.0×ULN. Secondary endpoints were change in IGF-I level, change in Acromegaly Symptom Diary (ASD) score, and maintenance of mean 5-sample growth hormone (GH) 999.99; P<.0001). Paltusotine was also superior to placebo for all secondary endpoints: mean (±SE) change in IGF-I of 0.04±0.09×ULN versus 0.83±0.1×ULN (P<.0001); mean (±SE) change in ASD score of –0.6±1.5 versus 4.6±1.6 (P=.02); mean GH maintained at P=.0003). The most common adverse events were acromegaly symptoms and gastrointestinal effects characteristic of SRLs. Conclusion Replacement of injected SRLs by once-daily oral paltusotine was effective in maintaining both biochemical and symptom control in patients with acromegaly and was well tolerated.
- 3 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (1) , 228-237
Open AccessAcromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine
Context Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. Objective To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs). Methods This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had insulin-like growth factor I (IGF-I) ≤1.0 times the upper limit of normal (×ULN) while receiving a stable dose of depot octreotide or lanreotide. Patients were switched from injected SRLs and randomized to receive paltusotine or placebo orally for 36 weeks. The primary endpoint was proportion of patients maintaining IGF-I ≤1.0×ULN. Secondary endpoints were change in IGF-I level, change in Acromegaly Symptom Diary (ASD) score, and maintenance of mean 5-sample growth hormone (GH) 999.99; P<.0001). Paltusotine was also superior to placebo for all secondary endpoints: mean (±SE) change in IGF-I of 0.04±0.09×ULN versus 0.83±0.1×ULN (P<.0001); mean (±SE) change in ASD score of –0.6±1.5 versus 4.6±1.6 (P=.02); mean GH maintained at P=.0003). The most common adverse events were acromegaly symptoms and gastrointestinal effects characteristic of SRLs. Conclusion Replacement of injected SRLs by once-daily oral paltusotine was effective in maintaining both biochemical and symptom control in patients with acromegaly and was well tolerated.
- 1 March 2022
- Published by Oxford University Press (OUP)
- p. 39-50
Pituitary Assessment Strategy
Accurate assessment of anterior pituitary function requires a sound knowledge of its normal physiology together with careful integration of clinical and biochemical information. The optimum methods of testing anterior and posterior pituitary function and the interpretation of the results are subjects of continuing debate. The syndromes associated with and consequences of hypo- and hyperpituitarism; and the diagnosis and treatment of diabetes insipidus are all discussed elsewhere in this book. The intention of this chapter is to describe the physiological basis and evidence in favour of the various available tests of anterior pituitary function, while at the same time acknowledging their limitations and appreciating the importance of the clinical context of testing.
- 1 March 2022
- Published by Oxford University Press (OUP)
- p. 39-50
Pituitary Assessment Strategy
Accurate assessment of anterior pituitary function requires a sound knowledge of its normal physiology together with careful integration of clinical and biochemical information. The optimum methods of testing anterior and posterior pituitary function and the interpretation of the results are subjects of continuing debate. The syndromes associated with and consequences of hypo- and hyperpituitarism; and the diagnosis and treatment of diabetes insipidus are all discussed elsewhere in this book. The intention of this chapter is to describe the physiological basis and evidence in favour of the various available tests of anterior pituitary function, while at the same time acknowledging their limitations and appreciating the importance of the clinical context of testing.
- 1 June 2020
- Published by Elsevier in European Journal of Cancer
- Vol. 132, 207-210
Adjuvant immunotherapy: the sting in the tail
- 1 June 2020
- Published by Elsevier in European Journal of Cancer
- Vol. 132, 207-210
Adjuvant immunotherapy: the sting in the tail
- Open Access
- 1 August 2018
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 179 (2) , 97-108
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
Objective: ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. Design: Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200 mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period. Methods: The primary efficacy measures were change in IGF-I at week 14, compared to baseline and between cohorts. For secondary endpoints (IGFBP3, acid labile subunit (ALS), GH, growth hormone-binding protein (GHBP)), comparison was between baseline and week 14. Safety was assessed by reported adverse events. Results and conclusions: Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups respectively. Compared to baseline, at week 14, twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% (P = 0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (P = 0.0012) greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and remained lower at week 21 than at baseline by a median of 18.7% (P = 0.0005). Compared to baseline, by week 14, IGFBP3 and ALS had declined by a median of 8.9% (P = 0.027) and 16.7% (P = 0.017) with twice-weekly ATL1103; GH had increased by a median of 46% at week 14 (P = 0.001). IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a median of 23.6% and 48.8% in the once- and twice-weekly cohorts (P = 0.027 and P = 0.005) respectively. ATL1103 was well tolerated, although 84.6% of patients experienced mild-to-moderate injection-site reactions. This study provides proof of concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 179 (2) , 97-108
Open AccessA randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
Objective: ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. Design: Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200 mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period. Methods: The primary efficacy measures were change in IGF-I at week 14, compared to baseline and between cohorts. For secondary endpoints (IGFBP3, acid labile subunit (ALS), GH, growth hormone-binding protein (GHBP)), comparison was between baseline and week 14. Safety was assessed by reported adverse events. Results and conclusions: Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups respectively. Compared to baseline, at week 14, twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% (P = 0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (P = 0.0012) greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and remained lower at week 21 than at baseline by a median of 18.7% (P = 0.0005). Compared to baseline, by week 14, IGFBP3 and ALS had declined by a median of 8.9% (P = 0.027) and 16.7% (P = 0.017) with twice-weekly ATL1103; GH had increased by a median of 46% at week 14 (P = 0.001). IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a median of 23.6% and 48.8% in the once- and twice-weekly cohorts (P = 0.027 and P = 0.005) respectively. ATL1103 was well tolerated, although 84.6% of patients experienced mild-to-moderate injection-site reactions. This study provides proof of concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly.
- 24 December 2015
- Published by Wiley in Clinical Endocrinology
- Vol. 84 (3) , 348-352
Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours
Chromogranin-A (CgA) and -B (CgB) are markers for monitoring disease status in patients with gastroenteropancreatic neuroendocrine tumours (NETs). These are specialised diagnostic tests often necessitating referral of specimens to a supra-regional assay service (SAS) laboratory for analysis. The aim of this audit was to assess if measurement of either plasma CgA or CgB alone provides sufficient clinical information in comparison to the current practice of measuring both markers together. A retrospective analysis was undertaken for all chromogranin tests requested for patients with a known NET diagnosis. Results were categorised based on whether plasma concentrations were elevated for one or both CgA and CgB. 325 sequential patients with a NET diagnosis had plasma chromogranin levels measured during the period of review. Baseline CgA was elevated in 60.9% of patients. Isolated elevations in CgA (with normal CgB) were found in 44.9% of patients, whilst combined elevations in both CgA and CgB were found in 16% of patients. Combined CgA and CgB concentrations within the normal range were observed for 38.5% of patients. Only 2 patients (0.6%) had an isolated elevation in CgB at baseline. Both patients had a diagnosis of pancreatic NET and were radiologically stable. Plasma CgA and CgB corresponded with disease stage (localised vs. metastatic). CgB in addition to CgA did not provide any significant improvement in diagnostic performance for identification of metastatic disease compared to CgA alone. Based on this NET population and specific assay performance characteristics, CgA alone provides sufficient information for the management of NET patients; the routine estimation of CgB in all patients is not informative in clinical practice.
- 24 December 2015
- Published by Wiley in Clinical Endocrinology
- Vol. 84 (3) , 348-352
Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours
Chromogranin-A (CgA) and -B (CgB) are markers for monitoring disease status in patients with gastroenteropancreatic neuroendocrine tumours (NETs). These are specialised diagnostic tests often necessitating referral of specimens to a supra-regional assay service (SAS) laboratory for analysis. The aim of this audit was to assess if measurement of either plasma CgA or CgB alone provides sufficient clinical information in comparison to the current practice of measuring both markers together. A retrospective analysis was undertaken for all chromogranin tests requested for patients with a known NET diagnosis. Results were categorised based on whether plasma concentrations were elevated for one or both CgA and CgB. 325 sequential patients with a NET diagnosis had plasma chromogranin levels measured during the period of review. Baseline CgA was elevated in 60.9% of patients. Isolated elevations in CgA (with normal CgB) were found in 44.9% of patients, whilst combined elevations in both CgA and CgB were found in 16% of patients. Combined CgA and CgB concentrations within the normal range were observed for 38.5% of patients. Only 2 patients (0.6%) had an isolated elevation in CgB at baseline. Both patients had a diagnosis of pancreatic NET and were radiologically stable. Plasma CgA and CgB corresponded with disease stage (localised vs. metastatic). CgB in addition to CgA did not provide any significant improvement in diagnostic performance for identification of metastatic disease compared to CgA alone. Based on this NET population and specific assay performance characteristics, CgA alone provides sufficient information for the management of NET patients; the routine estimation of CgB in all patients is not informative in clinical practice.
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
The burden of AIP mutations in pituitary adenoma patients from the UK
Introduction: Familial isolated pituitary adenoma (FIPA) and young-onset sporadic pituitary adenoma patients are suggested to be screened for mutations in AIP, a gene described in 2006 and amenable to UK testing since 2008. Methods: affected subjects have been tested in Exeter and Oxford genetic laboratories. Data were collected from 120 FIPA-families and 193 sporadic cases with young-onset disease (2 were used for statistical analysis. Results: We have identified 38 AIP pos kindreds (16 families and 22 simplex kindreds), representing 77 affected patients. In the 16 families (13.3% of FIPA-families), out of 211 members tested, 121 were carriers and 55 were affected. Of the 193 young simplex patients (44.5% GH-excess), 22 (11.4%) were AIPpos and 17 unaffected carrier family members were identified. 96 (60%) AIPpos carriers had a founder mutation: p.R304*, 79 subjects and p.F269_H275dup, 17 subjects. In the AIPpos FIPA kindreds, those affected were more frequently males (60.7 vs 41.1%, PPP=0.034) compared to AIPneg FIPA families. There were no differences in tumour size (77.6 vs 72.8% macroadenomas) or extrasellar extension (40 vs 39.8%). Of young sporadic cases, AIPpos patients were more frequently males (81.8 vs 46.8%, P=0.003), with larger adenomas (100% vs 80.3% macroadenomas, P=0.043) and extrasellar extension (100 vs 50%, P=0.004), but no differences in age-of-onset (18(13.5–23) vs 20 (15–25)) or pituitary apoplexy. GH&GH/PRL-secreting adenomas were more frequent in AIPpos compared to AIPneg cases (FIPA: 76.8 vs 31%, PPAIP mutations are found in 13.3% of families and 11.4% of young-onset patients. The two founder mutations identified are responsible for over half of the affected and unaffected carrier cases.
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
The burden of AIP mutations in pituitary adenoma patients from the UK
Introduction: Familial isolated pituitary adenoma (FIPA) and young-onset sporadic pituitary adenoma patients are suggested to be screened for mutations in AIP, a gene described in 2006 and amenable to UK testing since 2008. Methods: affected subjects have been tested in Exeter and Oxford genetic laboratories. Data were collected from 120 FIPA-families and 193 sporadic cases with young-onset disease (2 were used for statistical analysis. Results: We have identified 38 AIP pos kindreds (16 families and 22 simplex kindreds), representing 77 affected patients. In the 16 families (13.3% of FIPA-families), out of 211 members tested, 121 were carriers and 55 were affected. Of the 193 young simplex patients (44.5% GH-excess), 22 (11.4%) were AIPpos and 17 unaffected carrier family members were identified. 96 (60%) AIPpos carriers had a founder mutation: p.R304*, 79 subjects and p.F269_H275dup, 17 subjects. In the AIPpos FIPA kindreds, those affected were more frequently males (60.7 vs 41.1%, PPP=0.034) compared to AIPneg FIPA families. There were no differences in tumour size (77.6 vs 72.8% macroadenomas) or extrasellar extension (40 vs 39.8%). Of young sporadic cases, AIPpos patients were more frequently males (81.8 vs 46.8%, P=0.003), with larger adenomas (100% vs 80.3% macroadenomas, P=0.043) and extrasellar extension (100 vs 50%, P=0.004), but no differences in age-of-onset (18(13.5–23) vs 20 (15–25)) or pituitary apoplexy. GH&GH/PRL-secreting adenomas were more frequent in AIPpos compared to AIPneg cases (FIPA: 76.8 vs 31%, PPAIP mutations are found in 13.3% of families and 11.4% of young-onset patients. The two founder mutations identified are responsible for over half of the affected and unaffected carrier cases.
- Open Access
- 10 July 2015
- Published by Springer Nature in Hormones
- Vol. 15 (1) , 118-21
Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization
A male patient presented at the age of 54 years with metastatic pancreatic neuroendocrine tumour (NET). He was managed with interferon and multiple courses of MIBG therapy which controlled his disease for about seven years. He then developed symptomatic hypoglycaemia which resolved with the introduction of somatostatin analogue treatment and further therapeutic MIBG. However, three years later he was admitted to hospital with severe and intractable hypoglycaemia, which persisted despite treatment with dietary manipulation, diazoxide, long-acting octreotide injections, intravenous infusion of dextrose and octreotide and everolimus. Bland hepatic embolization was attempted as a last resort and resulted in prompt and dramatic improvement of his condition with no hypoglycaemia for five months. We recommend that hepatic embolization should be considered in patients with advanced and metastatic NETs accompanied by refractory hypoglycaemia, with the aim of symptomatic relief and palliation, and possibly some survival benefit.
- 10 July 2015
- Published by Springer Nature in Hormones
- Vol. 15 (1) , 118-21
Open AccessIntractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization
A male patient presented at the age of 54 years with metastatic pancreatic neuroendocrine tumour (NET). He was managed with interferon and multiple courses of MIBG therapy which controlled his disease for about seven years. He then developed symptomatic hypoglycaemia which resolved with the introduction of somatostatin analogue treatment and further therapeutic MIBG. However, three years later he was admitted to hospital with severe and intractable hypoglycaemia, which persisted despite treatment with dietary manipulation, diazoxide, long-acting octreotide injections, intravenous infusion of dextrose and octreotide and everolimus. Bland hepatic embolization was attempted as a last resort and resulted in prompt and dramatic improvement of his condition with no hypoglycaemia for five months. We recommend that hepatic embolization should be considered in patients with advanced and metastatic NETs accompanied by refractory hypoglycaemia, with the aim of symptomatic relief and palliation, and possibly some survival benefit.
- Open Access
- 1 April 2015
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 100 (4) , 1699-1708
Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Background: A novel oral octreotide formulation was tested for efficacy and safety in a phase III, multicenter, open-label, dose-titration, baseline-controlled study in patients with acromegaly. Methods: We enrolled 155 complete or partially controlled patients (IGF-1 <1.3 × upper limit of normal [ULN], and 2-h integrated GH <2.5 ng/mL) receiving injectable somatostatin receptor ligand (SRL) for ≥3 months. Subjects were switched to 40 mg/d oral octreotide capsules (OOCs), and the dose escalated to 60 and then up to 80 mg/d to control IGF-1. Subsequent fixed doses were maintained for a 7-month core treatment, followed by a voluntary 6-month extension. Results: Of 151 evaluable subjects initiating OOCs, 65% maintained response and achieved the primary endpoint of IGF-1 <1.3 × ULN and mean integrated GH <2.5 ng/mL at the end of the core treatment period and 62% at the end of treatment (up to 13 mo). The effect was durable, and 85 % of subjects initially controlled on OOCs maintained this response up to 13 months. When controlled on OOCs, GH levels were reduced compared to baseline, and acromegaly-related symptoms improved. Of 102 subjects completing the core treatment, 86% elected to enroll in the 6-month extension. Twenty-six subjects who were considered treatment failures (IGF-1 ≥1.3 × ULN) terminated early, and 23 withdrew for adverse events, consistent with those known for octreotide or disease related. Conclusions: OOC, an oral therapeutic peptide, achieves efficacy in controlling IGF-1 and GH after switching from injectable SRLs for up to 13 months, with a safety profile consistent with approved SRLs. OOC appears to be effective and safe as an acromegaly monotherapy.
- 1 April 2015
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 100 (4) , 1699-1708
Open AccessSafety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Background: A novel oral octreotide formulation was tested for efficacy and safety in a phase III, multicenter, open-label, dose-titration, baseline-controlled study in patients with acromegaly. Methods: We enrolled 155 complete or partially controlled patients (IGF-1 <1.3 × upper limit of normal [ULN], and 2-h integrated GH <2.5 ng/mL) receiving injectable somatostatin receptor ligand (SRL) for ≥3 months. Subjects were switched to 40 mg/d oral octreotide capsules (OOCs), and the dose escalated to 60 and then up to 80 mg/d to control IGF-1. Subsequent fixed doses were maintained for a 7-month core treatment, followed by a voluntary 6-month extension. Results: Of 151 evaluable subjects initiating OOCs, 65% maintained response and achieved the primary endpoint of IGF-1 <1.3 × ULN and mean integrated GH <2.5 ng/mL at the end of the core treatment period and 62% at the end of treatment (up to 13 mo). The effect was durable, and 85 % of subjects initially controlled on OOCs maintained this response up to 13 months. When controlled on OOCs, GH levels were reduced compared to baseline, and acromegaly-related symptoms improved. Of 102 subjects completing the core treatment, 86% elected to enroll in the 6-month extension. Twenty-six subjects who were considered treatment failures (IGF-1 ≥1.3 × ULN) terminated early, and 23 withdrew for adverse events, consistent with those known for octreotide or disease related. Conclusions: OOC, an oral therapeutic peptide, achieves efficacy in controlling IGF-1 and GH after switching from injectable SRLs for up to 13 months, with a safety profile consistent with approved SRLs. OOC appears to be effective and safe as an acromegaly monotherapy.
- Open Access
- 24 March 2015
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 39 (2) , 81-86
Qualitätssicherung der Analytik von Wachstumshormon und Insulin-Like Growth Factor I bei Erkrankungen der somatotropen Achse
Zusammenfassung: Hintergrund: Eine zuverlässige Laboranalytik bildet einen Grundpfeiler für die Diagnostik, Therapie und Verlaufskontrolle von Wachstumsstörungen und Störungen der Sekretion von Wachstumshormon (GH) und Insulin-Like Growth Factor I (IGF-I). Die gegenwärtig verfügbaren kommerziellen Assays weisen jedoch Defizite auf, die zu großen Unterschieden der gemessenen Hormonkonzentrationen führen. Methode: Empfehlungen eines Expertenworkshops mit klinisch tätigen Endokrinologen aus Pädiatrie und Innerer Medizin sowie mit Labormedizinern unter Bezugnahme auf die Ergebnisse der interdisziplinären Konsensus-Konferenz in Keswick (Virginia, USA) aus dem Jahr 2009. Ergebnisse: Zu den von den Workshopteilnehmern geforderten Qualitätskriterien für GH- und IGF-I-Assays zählen die Verwendung einheitlicher Referenzstandards, die Dokumentation der analytischen Bedingungen – unter anderem in Bezug auf Kalibratoren, Bindungsepitope, Kreuzreaktivität und Methoden zur Trennung von Bindungsproteinen –, die Chargenkonstanz und eine geringe Interassay-Variabilität. Die Teilnehmer empfehlen, Grenzwerte und Referenzintervalle assayspezifisch unter Verwendung großer und gut charakterisierter Referenzpopulationen zu erarbeiten und die Assayqualität insbesondere im Bereich klinisch wichtiger Entscheidungsgrenzen zu beschreiben. Schlussfolgerungen: Diagnostikahersteller sollten verpflichtet werden, die Umsetzung der Qualitätskriterien regelmäßig zu überwachen und darüber Bericht zu erstatten. Nur Assays, die nach einheitlichen Qualitätsstandards evaluiert sind und im klinischen Kontext eingesetzt werden, erlauben eine rational begründete Diagnostik und Therapie von Patienten mit Störungen der GH-Sekretion und vermeiden unnötige Belastungen der Patienten und Kostenträger.
- 24 March 2015
- Published by Walter de Gruyter GmbH in Journal of Laboratory Medicine
- Vol. 39 (2) , 81-86
Open AccessQualitätssicherung der Analytik von Wachstumshormon und Insulin-Like Growth Factor I bei Erkrankungen der somatotropen Achse
Zusammenfassung: Hintergrund: Eine zuverlässige Laboranalytik bildet einen Grundpfeiler für die Diagnostik, Therapie und Verlaufskontrolle von Wachstumsstörungen und Störungen der Sekretion von Wachstumshormon (GH) und Insulin-Like Growth Factor I (IGF-I). Die gegenwärtig verfügbaren kommerziellen Assays weisen jedoch Defizite auf, die zu großen Unterschieden der gemessenen Hormonkonzentrationen führen. Methode: Empfehlungen eines Expertenworkshops mit klinisch tätigen Endokrinologen aus Pädiatrie und Innerer Medizin sowie mit Labormedizinern unter Bezugnahme auf die Ergebnisse der interdisziplinären Konsensus-Konferenz in Keswick (Virginia, USA) aus dem Jahr 2009. Ergebnisse: Zu den von den Workshopteilnehmern geforderten Qualitätskriterien für GH- und IGF-I-Assays zählen die Verwendung einheitlicher Referenzstandards, die Dokumentation der analytischen Bedingungen – unter anderem in Bezug auf Kalibratoren, Bindungsepitope, Kreuzreaktivität und Methoden zur Trennung von Bindungsproteinen –, die Chargenkonstanz und eine geringe Interassay-Variabilität. Die Teilnehmer empfehlen, Grenzwerte und Referenzintervalle assayspezifisch unter Verwendung großer und gut charakterisierter Referenzpopulationen zu erarbeiten und die Assayqualität insbesondere im Bereich klinisch wichtiger Entscheidungsgrenzen zu beschreiben. Schlussfolgerungen: Diagnostikahersteller sollten verpflichtet werden, die Umsetzung der Qualitätskriterien regelmäßig zu überwachen und darüber Bericht zu erstatten. Nur Assays, die nach einheitlichen Qualitätsstandards evaluiert sind und im klinischen Kontext eingesetzt werden, erlauben eine rational begründete Diagnostik und Therapie von Patienten mit Störungen der GH-Sekretion und vermeiden unnötige Belastungen der Patienten und Kostenträger.
- Open Access
- 1 December 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (12) , 4434-4437
Case for the Wider Adoption of Mass Spectrometry-Based Adrenal Steroid Testing, and Beyond
Disclosure Summary: P.J.M. and P.J.T. have received research funding from Immunodiagnostic Systems PLC. The other authors have nothing to declare.
- 1 December 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (12) , 4434-4437
Open AccessCase for the Wider Adoption of Mass Spectrometry-Based Adrenal Steroid Testing, and Beyond
Disclosure Summary: P.J.M. and P.J.T. have received research funding from Immunodiagnostic Systems PLC. The other authors have nothing to declare.